This unique report provides information and analysis not available from any other published source. The database provides the 2024 supplier shares and strategies, the 2024-2029 volume and sales forecasts for over 40 immunohematology and NAT assays, as well as comprehensive lists of companies developing or marketing new technologies and products by test, including:
Blood Typing and Grouping Tests
ABO, Antibody Panels, Antibody Screening/Indirect Antiglobulin, Antigen Typing (C, c, Duffy, E, e, I, i, Kell, Kidd, Le a, b, MN, P, S, s), Antiglobulin (Direct, C3 + IgG, IgG, C3), Crossmatching (Immediate Spin, Full Crossmatch), Rh (D, Du)Infectious Disease Screening Tests
AIDS (HIV NAT, HIV-1/2), Cytomegalovirus, Hepatitis (HAV NAT, HBV NAT, HBs Ag, Anti-HBc, HCV NAT, HCV, ALT/SGPT), HTLV-I/II, Parvovirus B19 NAT, Syphilis, West Nile Virus NATThe companies analyzed in the report include:
- Abbott
- Beckman Coulter/Danaher
- Becton Dickinson
- Biokit
- bioMerieux
- Bio-Rad
- Diagast
- DiaSorin
- Fujirebio
- Grifols
- Hologic
- Immucor
- LabCorp
- Proteome Sciences
- Quest Diagnostics
- QuidelOrtho
- Roche
- Siemens Healthineers
- Tecan
- Thermo Fisher
